Injection timing and consistency Consistency matters more than the specific day or time
Retatrutide Dosing Schedule: Phase 3 Trial Updates The Phase 3 TRIUMPH trial program is evaluating retatrutide at doses that build on the Phase 2 trial findings
When to Consider Testing Testing may be useful: Before starting a GLP-1 medicine After a meaningful treatment change When diabetes goals are not being met When persistent gastrointestinal symptoms develop When food or fluid intake has significantly decreased When kidney or liver risk is already present When a prior result was abnormal When a healthcare provider recommends follow-up Testing frequency should be based on individual risk rather than an automatic monthly or quarterly panel for everyone
Retatrutide is a multi-receptor peptide agonist targeting GLP-1, GIP, and glucagon receptors, designed for advanced metabolic research
A lower starting dose may also help patients maintain consistency while progressing gradually
Groups of male mice (1213 weeks, 22.528.5 g, 56 mice/23 cages/group) were fasted for 4 h prior to IP injection of unfused WT albumin (0.9 mg/kg) or GLP-1 albumin fusions (1 mg/kg)